There are limited data to guide treatment recommendations for children with acute, symptomatic coronavirus disease 2019 (COVID-19). This review outlines a proposed management approach for children based on the published evidence to date and the approval of medications through drug regulatory agencies, as well as the known safety profile of the recommended drugs in this age group.
There are limited data on the best approach to managing azole-induced
hepatotoxicity. One described approach is switching between different
triazole agents to prevent the need for intravenous therapy. This case
series describes the outcomes of this approach in seven children. The
most common azole switch was voriconazole to fluconazole (3/7), followed
by fluconazole to voriconazole (2/7). One child each switched from
voriconazole to itraconazole, and posaconazole to fluconazole. Of the
seven cases, five had Grade 3 liver injury and two had Grade 2 liver
injury. These LFT abnormalities were deemed as ‘possibly’ in four cases,
and ‘probably’ in three cases to be related to the first azole
antifungal as per the Naranjo criteria. All had improvement in their LFT
abnormalities after the switch to an alternative azole antifungal. These
data suggest that switching azole antifungals offers a potential
treatment approach to azole-induced hepatotoxicity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.